Simulations Plus(NASDAQ:SLP) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Apr 13, 2016. Company reported revenue of $5.16M. Analysts estimated a revenue of $5.00M. Earnings per share were $0.07. Analysts had estimated an EPS of $0.07.
Simulations Plus (SLP) shares turned negative on Fridays trading session with the shares closing down -0.07 points or -0.80% at a volume of 23,348. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $8.772. The peak price level was also seen at $8.772 while the days lowest was $8.6001. Finally the shares closed at $8.66. The 52-week high of the shares is $11.8899 while the 52-week low is $5.52. According to the latest information available, the market cap of the company is $147 M.
Several Insider Transactions has been reported to the SEC. On Feb 2, 2016, Walter S Woltosz (CEO) sold 58,181 shares at $11.27 per share price.
Simulations Plus Inc. (Simulations Plus) develops and produces software for use in pharmaceutical research and for education and provides consulting and contract research services to the pharmaceutical industry. The Company offers five software products for pharmaceutical research. ADMET (Absorption Distribution Metabolism Excretion and Toxicity) Predictor is a computer program that takes molecular structures as inputs and predicts over 140 different properties for them at the rate of about 200000 compounds per hour. MedChem Designer includes a small set of ADMET Predictor property predictions allowing the chemist to modify molecular structures. MedChem Studio is a tool for medicinal and computational chemists for both data mining and for designing new drug-like molecules. DDDPlus simulates in-vitro laboratory experiments used to measure the rate of dissolution of the drug. GastroPlus simulates the absorption pharmacokinetics and pharmacodynamics of drugs.